QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
NASDAQ:TGTX

TG Therapeutics - TGTX Stock Forecast, Price & News

$18.07
+0.71 (+4.09%)
(As of 02/6/2023 02:15 PM ET)
Add
Compare
Today's Range
$16.91
$18.68
50-Day Range
$7.52
$17.97
52-Week Range
$3.48
$18.68
Volume
2.70 million shs
Average Volume
5.54 million shs
Market Capitalization
$2.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.80

TG Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
7.0% Downside
$16.80 Price Target
Short Interest
Bearish
16.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.75mentions of TG Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$333,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

576th out of 1,027 stocks

Pharmaceutical Preparations Industry

277th out of 500 stocks

TGTX stock logo

About TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Stock News Headlines

TG Therapeutics (NASDAQ:TGTX) Reaches New 52-Week High at $17.95
TG Therapeutics Sees Unusually Large Options Volume (NASDAQ:TGTX)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
TG Therapeutics: Strategy After Briumvi Launch
TG Therapeutics (NASDAQ:TGTX) PT Raised to $25.00
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
TGTX TG Therapeutics, Inc.
Analyst Ratings for TG Therapeutics
B.Riley Financial Keeps Their Buy Rating on TG Therapeutics (TGTX)
What's Going On With TG Therapeutics Shares
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Company Calendar

Last Earnings
11/10/2022
Today
2/06/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
286
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.80
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
-7.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-348,100,000.00
Net Margins
-4,749.83%
Pretax Margin
-4,749.87%

Debt

Sales & Book Value

Annual Sales
$6.69 million
Book Value
$1.68 per share

Miscellaneous

Free Float
132,843,000
Market Cap
$2.63 billion
Optionable
Optionable
Beta
2.02

Key Executives

  • Michael Sean WeissMichael Sean Weiss
    Chairman, President & Chief Executive Officer
  • Sean A. PowerSean A. Power
    Chief Financial Officer, Secretary & Treasurer
  • Owen A. O'Connor
    Chief Scientific Officer
  • Adam Waldman
    Chief Commercial Officer
  • Jenna A. Bosco
    Senior Vice President-Corporate Communications













TGTX Stock - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TGTX, but not buy additional shares or sell existing shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price forecast for 2023?

6 brokers have issued 1-year target prices for TG Therapeutics' stock. Their TGTX share price forecasts range from $6.00 to $25.00. On average, they expect the company's share price to reach $16.80 in the next twelve months. This suggests that the stock has a possible downside of 7.4%.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2023?

TG Therapeutics' stock was trading at $11.83 on January 1st, 2023. Since then, TGTX stock has increased by 53.3% and is now trading at $18.14.
View the best growth stocks for 2023 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Thursday, November, 10th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. The biopharmaceutical company earned $0.09 million during the quarter, compared to the consensus estimate of $3.37 million. TG Therapeutics had a negative net margin of 4,749.83% and a negative trailing twelve-month return on equity of 149.86%.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Hennion & Walsh Asset Management Inc. (0.09%), Moody Aldrich Partners LLC (0.07%), Bank of Montreal Can (0.00%), Nisa Investment Advisors LLC (0.05%) and Quantum Private Wealth LLC (0.03%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $18.14.

How much money does TG Therapeutics make?

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $2.64 billion and generates $6.69 million in revenue each year. The biopharmaceutical company earns $-348,100,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does TG Therapeutics have?

The company employs 286 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.

This page (NASDAQ:TGTX) was last updated on 2/6/2023 by MarketBeat.com Staff